Eargo (EAR) Cash-to-Debt : 6.01 (As of Sep. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Eargo Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Eargo's cash to debt ratio for the quarter that ended in Sep. 2023 was 6.01.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Eargo could pay off its debt using the cash in hand for the quarter that ended in Sep. 2023.

The historical rank and industry rank for Eargo's Cash-to-Debt or its related term are showing as below:

EAR' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.55 Med: 6.45 Max: 15.34
Current: 6.01

During the past 6 years, Eargo's highest Cash to Debt Ratio was 15.34. The lowest was 0.55. And the median was 6.45.

EAR's Cash-to-Debt is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 1.91 vs EAR: 6.01

Eargo Cash-to-Debt Historical Data

The historical data trend for Eargo's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Eargo Cash-to-Debt Chart

Eargo Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Cash-to-Debt

Get a 7-Day Free Trial

7.30

1.09

13.23

4.88

15.34

Eargo Quarterly Data
	Dec17	Dec18	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Cash-to-Debt	Get a 7-Day Free Trial															0.67	15.34	10.15	7.78	6.01

Competitive Comparison of Eargo's Cash-to-Debt

For the Medical Devices subindustry, Eargo's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eargo's Cash-to-Debt Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Eargo's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Eargo's Cash-to-Debt falls into.

Eargo Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Eargo's Cash to Debt Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	101.238	/	(0.628	+	5.973)
	=	15.34

Eargo's Cash to Debt Ratio for the quarter that ended in Sep. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	46.023	/	(0.624	+	7.03)
	=	6.01

Eargo (NAS:EAR) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Eargo Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Eargo's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Eargo (EAR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Eargo Inc (NAS:EAR) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

2665 North First Street, Suite 300, San Jose, CA, USA, 95134

Website

https://www.eargo.com

Eargo Inc is a medical device company, focused on improving the quality of life of people with hearing loss. The company offers hearing aids, professional support services, and other insurance-related services through a direct-to-consumer format with a personalized, consumer-centric approach. The product portfolio includes Eargo Neo HiFi, Eargo 5, Eargo 6, Eargo 7, and related accessories.

Executives

Mark Thorpe	officer: Chief Accounting Officer	C/O EARGO, INC., 2665 NORTH FIRST STREET, SUITE 300, SAN JOSE CA 95134
William Brownie	officer: Chief Operating Officer	C/O EARGO, INC., 2665 NORTH FIRST STREET, SUITE 300, SAN JOSE CA 95134
Adam Laponis	officer: Chief Financial Officer	C/O EARGO, INC., 2665 NORTH FIRST STREET, SUITE 300, SAN JOSE CA 95134
Christian Gormsen	director, officer: President and CEO	C/O EARGO, INC., 2665 NORTH FIRST STREET, SUITE 300, SAN JOSE CA 95134
Trit Garg	director	C/O PATIENT SQUARE EQUITY ADVISORS, LP, 2884 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
Afshin Justin Sabet-peyman	director	C/O PATIENT SQUARE EQUITY ADVISORS, LP, 2884 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
Onkarr Narula	director	C/O PATIENT SQUARE EQUITY ADVISORS, LP, 2884 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
Donald J Spence	director	C/O OAKMONT ACQUISITION CORP., 33 BLOOMFIELD HILLS PARKWAY, SUITE 240, BLOOMFIELD HILLS MI 48304
Psc Echo Gp, Llc	10 percent owner	2884 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
Psc Echo, Lp	10 percent owner	2884 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
David James Wu	director	411 FIRST AVENUE SOUTH, SUITE 600, SEATTLE WA 98104
Nina Richardson	director	C/O SILICON LABORATORIES, 400 W CESAR CHAVEZ, AUSTIN TX 78701
Katie J Bayne	director	C/O EARGO, INC., 2665 NORTH FIRST STREET, SUITE 300, SAN JOSE CA 95134
Geoff Pardo	director	26 TECHNOLOGY DRIVE, IRVINE CA 92618
Gilde Healthcare Holding B.v.	10 percent owner	NEWTONLAAN 91, PO BOX 85067, 3508 UTRECHT P7 AB